On April 18, 2026, President Trump signed an executive order at the White House directing the FDA to expedite its review of psychedelic drugs that have been designated as breakthrough therapies for treating serious mental illness. He was surrounded by medical professionals and veterans. He credited Joe Rogan for making it happen.
“I got a call from a number of people, including the great Joe Rogan,” Trump told reporters at the signing ceremony. “And he said, ‘We have to do something about this.’”
So he did. Because in this administration, executive policy starts with a podcast host picking up the phone.
What the Executive Order Does
The order directs the FDA Commissioner to issue National Priority Vouchers to psychedelic drugs that have received Breakthrough Therapy designations for treating serious mental illness. It creates a pathway for patients to access investigational psychedelics — including ibogaine — under Trump’s Right to Try Act. It orders the Attorney General to begin rescheduling reviews as soon as Phase 3 clinical trials are complete. And it commits $50 million through ARPA-H to match state-level investments in psychedelic research.
Since September 11, 2001, the United States has lost 21 times more veteran lives to suicide than on the battlefield. That number is staggering and undeniable. A 2024 Stanford study found that 30 special operations veterans with traumatic brain injuries who underwent ibogaine treatment experienced an 80–90% reduction in depression and anxiety symptoms within one month. The science is promising. The need is urgent. None of that is in question.
What Is in Question
The FDA’s safety review process exists because drugs kill people when they aren’t properly tested. The executive order doesn’t just encourage the FDA to move faster — it directs the agency to clear away “bureaucratic hurdles” for drugs that haven’t completed the approval process. It opens Right to Try access for ibogaine, a drug that bipartisan legislation was already working through Congress to handle responsibly — with proper VA infrastructure, clinical standards, and safety protocols.
Trump skipped all of that. He signed a photo-op order and name-dropped Joe Rogan.
“This has probably never been — anything happen so quickly,” Trump said at the ceremony. “Everybody is so strongly in favor of this.”
Not everybody. The FDA rejected MDMA-assisted therapy for PTSD in August 2024 over safety concerns about clinical trial methodology. Ibogaine is classified as a Schedule I substance in the United States and has been linked to cardiac events and deaths in uncontrolled settings. The science is promising, but the science also requires the safety infrastructure Trump is ordering the government to cut corners on.
The Hypocrisy
This is the same administration whose VA Secretary Doug Collins faced bipartisan grilling this week over proposed staffing cuts and a sweeping reorganization of the Veterans Health Administration. Lawmakers from both parties raised concerns that the overhaul risks disrupting care for veterans already struggling to access services.
So while the VA is cutting staff, closing programs, and making it harder for veterans to see a doctor — the president is signing executive orders to fast-track experimental drugs because a podcaster asked him to.
Meanwhile, a bipartisan bill introduced March 27 by Senators Tim Sheehy (R-MT), Ruben Gallego (D-AZ), Tammy Duckworth (D-IL), and John Boozman (R-AR) would have created a dedicated Office of Novel Therapeutics within the VA to properly implement psychedelic treatments — with clinical standards, safety protocols, workforce training, and oversight. It was the responsible way to do this.
Trump didn’t wait for it. He didn’t mention it. He signed an executive order and thanked Joe Rogan.
The Pattern
This is how it works. Veterans are suffering. The crisis is real. Instead of building the infrastructure to help them — adequately staffing the VA, funding clinical programs, passing bipartisan legislation with proper guardrails — the administration signs a flashy executive order that sounds like action but is really a press release with a presidential seal on it.
The $50 million in ARPA-H funding is real. The Right to Try expansion is real. But without the VA workforce to implement it, without proper clinical infrastructure, without the guardrails that Congress was already building — it’s a headline, not a healthcare plan.
Texas committed $50 million for ibogaine research on its own. Congress was legislating. The FDA was reviewing. None of that required Joe Rogan to call the president. But this required Joe Rogan to call the president. And that tells you everything about how decisions get made in this White House.
Sources
- Fox News: Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs. Full transcript of signing ceremony remarks. April 18, 2026.
- White House Fact Sheet: Full details of the executive order — National Priority Vouchers, Right to Try pathway for ibogaine, $50M ARPA-H allocation, DEA rescheduling directive, VA/FDA collaboration. April 18, 2026.
- Military.com: Senate Bill 4220 (Veterans Health Administration Novel Therapeutics Preparedness Act), introduced March 27 by Sheehy (R-MT) and Gallego (D-AZ), would create VA Office of Novel Therapeutics with clinical standards, safety protocols, and workforce training. April 6, 2026.
- Washington Examiner: VA Secretary Collins faced bipartisan questioning over proposed staffing cuts and VHA reorganization; lawmakers raised concerns about disrupting veteran care. January 30, 2026.